Skip to main content
Premium Trial:

Request an Annual Quote

Biogen Licenses the Rosetta Resolver Expression Analysis System

NEW YORK, April 25 - Biogen has licensed the Rosetta Resolver gene expression analysis system from Rosetta Inpharmatics, the companies said Wednesday.

Biogen will use the Resolver system to manage and analyze its gene expression data, the pharmaceutical company said in a statement. The companies did not disclose financial details of the deal.

"The latest version of the system is geared specifically to organizations like Biogen, with expertise in gene expression research and a need for high-throughput analysis of Affymetrix GeneChip and other types of microarray data," Stephen Friend, CEO of Rosetta Inpharmatics, said in a statement.

The Resolver system accepts data from a wide variety of expression profiling formats, including Affymetrix GeneChip and Agilent DNA microarrays, and applies proprietary error models to calculate statistics on the gene expression data. Rosetta released version 2.0 of the system last quarter and has granted Agilent Technologies exclusive distribution rights to it.  

Rosetta's other licensees for the Resolver include the Harvard Center for Genomic Research, Immunex, Paradigm Genetics, and GlaxoSmithKline. Rosetta has also penned deals to use the technology in collaboration with Abbott Labs, Gemini Genomics, Monsanto, and Sangamo Biosciences.   
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.